Cite

HARVARD Citation

    Rosen, N. et al. (2019). Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine. Headache. 59 (4), pp. 627-628. [Online]. 
  
Back to record